TNGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tango Therapeutics Inc (TNGX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive developments in the pipeline, the recent price drop, mixed analyst ratings, lack of strong trading trends, and absence of significant positive catalysts suggest a cautious approach. The stock may be worth monitoring for future developments, but it does not present a compelling entry point right now.
The technical indicators are mixed. The MACD is positive but contracting, suggesting weakening momentum. The RSI is neutral at 45.132, indicating no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the recent sharp price drop (-13.38% in regular market trading) raises concerns about near-term stability. Key support levels are at 22.139 and 18.608, with resistance at 33.571 and 37.102.
Several analysts have raised price targets recently, citing potential in the PRMT5 inhibitor + RAS(ON) inhibitor combination for pancreatic ductal adenocarcinoma. Leerink views the current price drop as a buying opportunity ahead of key data expected by year-end. The company's strategic shift to focus on first-line pancreatic cancer treatment could yield better long-term results.
Piper Sandler and Jefferies downgraded the stock, citing concerns about the company's pivot away from vopimetostat monotherapy trials and valuation concerns after a significant year-to-date price increase. The departure of two board members has also raised questions about internal stability. Additionally, there are no significant hedge fund or insider trading trends to support a strong buy.
No financial data is available for analysis due to an error in the provided data.
Analyst ratings are mixed. Some firms, like Leerink and Wedbush, have raised price targets and maintained Outperform ratings, while others, like Piper Sandler and Jefferies, have downgraded the stock to Neutral or Hold due to concerns about valuation and strategic shifts. The price targets range from $24 to $55, reflecting uncertainty about the stock's future performance.
